Akerna (KERN) Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akerna in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KERN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KERN, but not buy additional shares or sell existing shares.
View KERN analyst ratings or view top-rated stocks.

1 analysts have issued 12 month target prices for Akerna's stock. Their KERN share price forecasts range from $1.00 to $1.00. On average, they expect the company's share price to reach $1.00 in the next year. This suggests a possible upside of 428.5% from the stock's current price.
View analysts price targets for KERN or view top-rated stocks among Wall Street analysts.

Akerna's stock was trading at $0.6902 at the start of the year. Since then, KERN shares have decreased by 72.6% and is now trading at $0.1892.
View the best growth stocks for 2023 here.

Akerna saw a increase in short interest in September. As of September 15th, there was short interest totaling 123,400 shares, an increase of 1,032.1% from the August 31st total of 10,900 shares. Based on an average trading volume of 315,800 shares, the days-to-cover ratio is currently 0.4 days. Approximately 1.9% of the company's stock are sold short.
View Akerna's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our KERN earnings forecast.

Akerna Corp. (NASDAQ:KERN) released its quarterly earnings data on Monday, August, 14th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.20. The business had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.66 million. Akerna had a negative trailing twelve-month return on equity of 475.50% and a negative net margin of 251.68%.

Amplify Seymour Cannabis ETF holds 13,319 shares of KERN stock, representing 0.03% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akerna investors own include KushCo (KSHB), Organigram (OGI), Supreme Cannabis (SPRWF), Auxly Cannabis Group (CBWTF), Charlotte's Web (CWBHF), Medical Marijuana (MJNA), MariMed (MRMD), Matinas BioPharma (MTNB), CNBX Pharmaceuticals (CNBX) and DHT (DHT).

Akerna trades on the NASDAQ under the ticker symbol "KERN."

Shares of KERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KERN stock can currently be purchased for approximately $0.19.

Akerna (NASDAQ:KERN) has a market capitalization of $1.48 million and generates $13.65 million in revenue each year. The company earns $-79,060,000.00 in net income (profit) each year or ($7.37) on an earnings per share basis.

The company employs 112 workers across the globe.

Akerna's mailing address is 1601 ARAPAHOE STREET, DENVER CO, 80202. The official website for the company is www.akerna.com. The company can be reached via phone at 888-932-6537 or via email at ir@akerna.com.